Project Grant R01FD008443
Award Date
9/15/24
Completion Date
6/30/29
Dollars Obligated
$650K
Funding Federal Agency
Office of Medical Products and Tobacco
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award, valued at $1,723,610.00 and awarded by the U.S. Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103), will support the development of novel gene therapy treatments and outcome measures for Leber Congenital Amaurosis (LCA) in pediatric patients. The award has two key objectives: 1) Conduct a Phase I/II clinical trial of a gene augmentation therapy for LCA5, a severe form of LCA, in adolescent patients aged 13-18 years, and 2) Develop new...
This $503,194 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Seattle Children's Hospital aimed at developing an innovative multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key products and services being delivered under this 2-year award include: 1) Determining the efficacy of the R2P3 MTE, which binds to the ROR1 and PD-L1 tumor targets as well as CD3 on T cells,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $792,367 to Nanopharmaceuticals LLC to develop a novel dual-targeting ligand, NP855, for the treatment of high-risk neuroblastoma. The key products and services to be delivered under this grant include: Scaled-up manufacturing and analytical evaluation of the NP855 drug substance to enable formulation of the drug product. In vitro and in vivo studies to confirm the efficacy of the...
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The funded research aims to target the extracellular glucose-regulated protein 78 (eGRP78) expressed on the surface of drug-resistant tumor cells, in order to induce apoptosis, eliminate drug and immune resistance, and reduce the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding for the preclinical development of an EYA2 tyrosine phosphatase inhibitor as a potential therapeutic for medulloblastoma, the most common malignant brain tumor in children. The $399,709 award to Sieyax, Inc. (a woman-owned small business) will support two primary objectives: 1) Optimizing the synthesis and evaluating the drug metabolism, pharmacokinetics, and toxicity...
The federal Project Grant award of $598,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research conducted by Children's Hospital Los Angeles (CHLA) to establish a cutoff for minimal residual intraocular disease in retinoblastoma using extracellular vesicles from aqueous humor liquid biopsy. The award, effective August 1, 2025 through July 31, 2028, will fund this innovative medical research project aimed at transforming...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $371,070 to Resonant Therapeutics, Inc. to develop a novel nectin-targeting antibody-drug conjugate (ADC) for the treatment of ovarian cancer. The funding will be used to refine the target patient population, determine the optimal payload, and establish preclinical dosing for the ADC. This represents an important advancement, as current ADC treatments for ovarian cancer are...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope provides $738,698 to develop a novel combination therapy for treating relapsed and refractory acute myelogenous leukemia (AML) in older patients. The key product being developed is a targeted radiotherapy approach that combines total marrow irradiation (TMLI) with an anti-CD38 targeted alpha therapy (TAT) using the monoclonal antibody...